|Chemical and physical data|
|Molar mass||146.3 kg/mol (peptide) g·mol−1|
|(what is this?)|
Gantenerumab is currently being evaluated in a prodromal Alzheimer's disease population in the Scarlet Road study, a global phase II study of approximately 360 subjects in 100 centers in 15 countries.
One clinical study was stopped on December 19, 2014 after disappointing results.
As of late 2014, Phase III clinical trials are ongoing.
- Statement On A Nonproprietary Name Adopted By The Usan Council - Gantenerumab American Medical Association.
- International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
- Clinical trial number NCT00531804 for "A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease" at ClinicalTrials.gov
- H. Spreitzer (10 November 2014). "Neue Wirkstoffe – Gantenerumab". Österreichische Apothekerzeitung (in German) (23/2014): 55.
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|